Humacyte, Inc.
HUMA
Rank in Stocks
#18646
Humacyte, Inc. focuses on developing and manufacturing readily available,... Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Share Price
$0.4552
Last synced: 2026-11-09
Market Cap
$126.45M
Change (1 day)
1.56%
Change (1 year)
-64.44%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Humacyte, Inc. (HUMA)
Category
Healthcare
EPS for Humacyte, Inc. (HUMA)
EPS as of June 2026 TTM: $-0.51
According to Humacyte, Inc.'s latest financial reports, its current EPS (TTM) is $-0.51. At the end of 2025 the company had an EPS of $-0.26, an increase over its 2024 EPS of $-1.26.
EPS history for Humacyte, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.51 | 96.15% |
| 2025 | $-0.26 | -79.37% |
| 2024 | $-1.26 | 17.76% |
| 2023 | $-1.07 | 791.67% |
| 2022 | $-0.12 | -81.82% |
| 2021 | $-0.66 | -88.04% |
| 2020 | $-5.52 | 29.88% |
| 2019 | $-4.25 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -3,170.59% |
US
|
|
| $-7.07 | 1,286.27% |
US
|
|
| $-5.29 | 937.25% |
AU
|
|
| $12.88 | -2,625.51% |
BE
|
|
| $21.56 | -4,327.45% |
NL
|
Questions about Humacyte, Inc.'s earnings per share (EPS)
What is Humacyte, Inc.'s earnings per share (EPS)?
Humacyte, Inc.'s earnings per share (EPS) over the last twelve months is $-0.51, as of Jun 2026.
What was Humacyte, Inc.'s earnings per share (EPS) in 2025?
In 2025, Humacyte, Inc.'s earnings per share (EPS) was $-0.26, compared with $-1.26 in 2024.
How has Humacyte, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Humacyte, Inc.'s earnings per share (EPS) was highest in 2022 ($-0.12) and lowest in 2020 ($-5.52).
How does Humacyte, Inc.'s earnings per share (EPS) compare with similar companies?
Humacyte, Inc.'s earnings per share (EPS) ($-0.51) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.